aTyr Pharma, Inc. (NASDAQ:ATYR) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Shares of aTyr Pharma, Inc. (NASDAQ:ATYR) have been assigned an average recommendation of “Moderate Buy” from the four research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $4.00.

Several equities research analysts have recently weighed in on the company. Wells Fargo & Company raised their price objective on aTyr Pharma from $1.00 to $4.00 and gave the stock an “equal weight” rating in a research note on Friday. Weiss Ratings lowered aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th. Finally, Wall Street Zen raised aTyr Pharma to a “hold” rating in a report on Saturday, October 31st.

Hedge Funds Weigh In On aTyr Pharma

A hedge fund recently raised its stake in aTyr Pharma stock. Bank of America Corp DE boosted its stake in shares of aTyr Pharma, Inc. (NASDAQ:ATYR) by 139.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 303,559 shares of the company’s stock after buying an additional 176,859 shares during the period. Bank of America Corp DE owned about 0.31% of aTyr Pharma worth $237,000 at the end of the most recent reporting period. 61.72% of the stock is owned by institutional investors.

aTyr Pharma Stock Up 9.5%

aTyr Pharma stock traded up $0.57 during mid-day trading on Friday, hitting $6.60. The company’s stock had a trading volume of 9,223 shares, compared to its average volume of 65,817. The stock has a market capitalization of $16.18 million, a P/E ratio of -0.27 and a beta of 1.04. aTyr Pharma has a twelve month low of $4.07 and a twelve month high of $44.40. The stock’s fifty day moving average price is $11.99 and its two-hundred day moving average price is $23.70.

aTyr Pharma (NASDAQ:ATYR) last posted its quarterly earnings results on Friday, November 6th. The company reported ($7.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.00) by ($3.43). Equities analysts expect that aTyr Pharma will post -17.80 earnings per share for the current year.

About aTyr Pharma

aTyr Pharma, Inc (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation.

aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.